About
Overview
Team
Management
Board of Directors
Scientific Advisory Board
Partnering
Technology
LYTAC Platform
Publications
Pipeline
Programs
Disease Area Focus
Careers
Culture
Benefits
Job Openings
Investors
Overview
News & Events
Press Releases
Events & Presentations
Stock
Stock Quote & Chart
Governance
Documents & Charters
Board of Directors
Management Team
Committee Composition
Financials
SEC Filings
Shareholder Services
Investor FAQs
Email Alerts
Contact Us
Contact
About
LCA-0321 is a novel targeted protein degrader designed to specifically and rapidly eliminate TSHR autoantibodies for the treatment of Graves’ disease
About
Overview
Team
Management
Board of Directors
Scientific Advisory Board
Partnering
Technology
LYTAC Platform
Publications
Pipeline
Programs
Disease Area Focus
Careers
Culture
Benefits
Job Openings
Investors
Overview
News & Events
Press Releases
Events & Presentations
Stock
Stock Quote & Chart
Governance
Documents & Charters
Board of Directors
Management Team
Committee Composition
Financials
SEC Filings
Shareholder Services
Investor FAQs
Email Alerts
Contact Us
Contact